Literature DB >> 34846645

The correlation of immunoscore and frailty in colorectal cancer.

Toshihiro Nakao1, Mitsuo Shimada2, Kozo Yoshikawa2, Takuya Tokunaga2, Masaaki Nishi2, Hideya Kashihara2, Chie Takasu2, Yuma Wada2, Toshiaki Yoshimoto2, Syoko Yamashita2, Yosuke Iwakawa2.   

Abstract

BACKGROUND: The Immunoscore is a useful prognostic and predictive factor for colorectal cancer. Frailty predicts overall and recurrence-free survival following resection of colorectal cancer, and the immunosuppressive state of frailty might affect tumor progression. This study investigated the relationship between the Immunoscore and frailty in colorectal cancer.
METHODS: This retrospective study included patients who underwent radical surgery for stage II and III colorectal cancer (n = 108). Patients were divided into frail (n = 11) and non-frail (n = 97) groups, and low (IS0-2) (n = 70) and high (IS3-4) Immunoscore groups (n = 38), for comparison.
RESULTS: American Society of Anesthesiologists physical status was higher, tumor diameter was larger, number of well-differentiated tumors was higher, albumin was lower, 5-year overall survival (OS) was lower (frail group: 50.0%, non-frail group: 90.5%, p < 0.001) and 5-year disease-free survival (DFS) was lower (frail group: 36.4%, non-frail group: 75.2%, p = 0.024) in the frail than in the non-frail group. Left colon cancer was more, 5-year OS was lower (IS0-2 group: 82.0%, IS3-4 group: 96.7%, p = 0.040) and 5-year DFS was lower (IS0-2 group: 66.3%, IS3-4 group: 83.3%, p = 0.043) in the IS0-2 than in the IS3-4 group. The Immunoscore was lower in the frail than in the non-frail group.
CONCLUSION: Immunoscore and frailty are prognostic and predictive factors in colorectal cancer, and they are correlated with each other. The immunosuppressive state from frailty might affect this correlation.
© 2021. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Colorectal cancer; Frailty; Immunoscore

Mesh:

Year:  2021        PMID: 34846645     DOI: 10.1007/s10147-021-02096-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  4 in total

1.  Ottawa Criteria for Appropriate Transfusions in Hepatectomy: Using the RAND/UCLA Appropriateness Method.

Authors:  Sean Bennett; Alan Tinmouth; Daniel I McIsaac; Shane English; Paul C Hébert; Paul J Karanicolas; Alexis F Turgeon; Jeffrey Barkun; Timothy M Pawlik; Dean Fergusson; Guillaume Martel
Journal:  Ann Surg       Date:  2018-04       Impact factor: 12.969

2.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Authors:  Anna S Berghoff; Elisabeth Fuchs; Gerda Ricken; Bernhard Mlecnik; Gabriela Bindea; Thomas Spanberger; Monika Hackl; Georg Widhalm; Karin Dieckmann; Daniela Prayer; Amelie Bilocq; Harald Heinzl; Christoph Zielinski; Rupert Bartsch; Peter Birner; Jerome Galon; Matthias Preusser
Journal:  Oncoimmunology       Date:  2015-06-09       Impact factor: 8.110

3.  STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.

Authors:  Yuan-Ming Pan; Cheng-Gang Wang; Min Zhu; Rui Xing; Jian-Tao Cui; Wen-Mei Li; De-Dong Yu; Shu-Bin Wang; Wei Zhu; Ying-Jiang Ye; Yun Wu; Shan Wang; You-Yong Lu
Journal:  Mol Cancer       Date:  2016-12-09       Impact factor: 27.401

4.  Elevated Expression of miR-19b Enhances CD8+ T Cell Function by Targeting PTEN in HIV Infected Long Term Non-progressors With Sustained Viral Suppression.

Authors:  Lin-Bo Yin; Cheng-Bo Song; Jie-Fu Zheng; Ya-Jing Fu; Shi Qian; Yong-Jun Jiang; Jun-Jie Xu; Hai-Bo Ding; Hong Shang; Zi-Ning Zhang
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

  4 in total
  1 in total

1.  Preoperative nutrition and exercise intervention in frailty patients with gastric cancer undergoing gastrectomy.

Authors:  Yuma Wada; Masaaki Nishi; Kozo Yoshikawa; Chie Takasu; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Toshiaki Yoshimoto; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2022-06-30       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.